23 related articles for article (PubMed ID: 25497216)
1. What can we learn from molecular dynamics simulations for GPCR drug design?
Tautermann CS; Seeliger D; Kriegl JM
Comput Struct Biotechnol J; 2015; 13():111-21. PubMed ID: 25709761
[TBL] [Abstract][Full Text] [Related]
2. 2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.
Watson PS; Jiang B; Harrison K; Asakawa N; Welch PK; Covington M; Stowell NC; Wadman EA; Davies P; Solomon KA; Newton RC; Trainor GL; Friedman SM; Decicco CP; Ko SS
Bioorg Med Chem Lett; 2006 Nov; 16(21):5695-9. PubMed ID: 16931001
[TBL] [Abstract][Full Text] [Related]
3. Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.
Bahl A; Barton P; Bowers K; Caffrey MV; Denton R; Gilmour P; Hawley S; Linannen T; Luckhurst CA; Mochel T; Perry MW; Riley RJ; Roe E; Springthorpe B; Stein L; Webborn P
Bioorg Med Chem Lett; 2012 Nov; 22(21):6694-9. PubMed ID: 23021991
[TBL] [Abstract][Full Text] [Related]
4. Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part I.
Furber M; Alcaraz L; Luckhurst C; Bahl A; Beaton H; Bowers K; Collington J; Denton R; Donald D; Kinchin E; MacDonald C; Rigby A; Riley R; Soars M; Springthorpe B; Webborn P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7702-6. PubMed ID: 23142617
[TBL] [Abstract][Full Text] [Related]
5. Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part II: optimising in vivo clearance.
Furber M; Alcaraz L; Luckhurst C; Bahl A; Beaton H; Bowers K; Collington J; Denton R; Donald D; Kinchin E; MacDonald C; Rigby A; Riley R; Soars M; Springthorpe B; Webborn P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7707-10. PubMed ID: 23116889
[TBL] [Abstract][Full Text] [Related]
6. Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.
De Lucca GV; Kim UT; Vargo BJ; Duncia JV; Santella JB; Gardner DS; Zheng C; Liauw A; Wang Z; Emmett G; Wacker DA; Welch PK; Covington M; Stowell NC; Wadman EA; Das AM; Davies P; Yeleswaram S; Graden DM; Solomon KA; Newton RC; Trainor GL; Decicco CP; Ko SS
J Med Chem; 2005 Mar; 48(6):2194-211. PubMed ID: 15771462
[TBL] [Abstract][Full Text] [Related]
7. CCR3 antagonists: a survey of the patent literature.
Gong L; Wilhelm RS
Expert Opin Ther Pat; 2009 Aug; 19(8):1109-32. PubMed ID: 19637977
[TBL] [Abstract][Full Text] [Related]
8. Small molecule antagonists for chemokine CCR3 receptors.
Willems LI; Ijzerman AP
Med Res Rev; 2010 Sep; 30(5):778-817. PubMed ID: 19967721
[TBL] [Abstract][Full Text] [Related]
9. Chemokine receptor antagonists: Part 1.
Pease JE; Horuk R
Expert Opin Ther Pat; 2009 Jan; 19(1):39-58. PubMed ID: 19441897
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4.
Pease JE; Horuk R
Expert Opin Drug Discov; 2014 May; 9(5):467-83. PubMed ID: 24641500
[TBL] [Abstract][Full Text] [Related]
11. Rodent selectivity of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists: insights from a receptor model.
Kriegl JM; Martyres D; Grundl MA; Anderskewitz R; Dollinger H; Rast G; Schmid B; Seither P; Tautermann CS
Bioorg Med Chem Lett; 2015 Jan; 25(2):229-35. PubMed ID: 25497216
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
